Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Moderate Buy” from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned an average rating of “Moderate Buy” from the twenty-three research firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $122.61.

Several research analysts have recently commented on SRPT shares. Evercore ISI lowered Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 price target for the company. in a research report on Thursday, May 8th. JPMorgan Chase & Co. reduced their price target on Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating for the company in a research report on Tuesday, May 20th. The Goldman Sachs Group reduced their price target on Sarepta Therapeutics from $178.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Morgan Stanley reduced their price target on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Finally, Scotiabank reduced their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research report on Thursday, March 20th.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in SRPT. Manchester Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the last quarter. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth about $31,000. Ancora Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 1.7%

SRPT opened at $39.54 on Friday. The firm has a market cap of $3.89 billion, a price-to-earnings ratio of 31.63 and a beta of 0.85. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12 month low of $34.10 and a 12 month high of $173.25. The stock has a fifty day moving average price of $48.86 and a 200-day moving average price of $90.33.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The company’s revenue was up 80.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.73 earnings per share. As a group, equities research analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.